This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/guide-to-pharmacology/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/mesh/concept/
n19http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/chemspider/
n6http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/wikipedia/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/kegg-compound/
owlhttp://www.w3.org/2002/07/owl#
n21http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n24http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/pubchem-substance/
n23http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/iuphar/
n16http://linked.opendata.cz/resource/drugbank/drug/DB06144/identifier/drugbank/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06144
rdf:type
n3:Drug
n3:description
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market.
n3:generalReferences
# Kane JM, Tamminga CA: Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Investig Drugs. 1997 Nov;6(11):1729-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15989577 # Lewis R, Bagnall AM, Leitner M: Sertindole for schizophrenia. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001715. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16034864 # Perquin LN: Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol. 2005 Nov;20(6):335-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16192844 # Murdoch D, Keating GM: Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16529528 # Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation. Prescrire Int. 2007 Apr;16(88):59-62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17458045 # Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16925508 # Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006 Dec 1;60(7):543-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16952163
n3:group
withdrawn approved
n3:halfLife
3 days
n3:indication
Used in the treatment of schizophrenia.
owl:sameAs
n6:DB06144 n10:DB06144
dcterms:title
Sertindole
adms:identifier
n8:PA164784002 n9:Sertindole n14:98 n15:C07567 n16:DB06144 n17:98 n18:9122 n19:54229 n20:46504717 n23:D00561 n24:60149
n3:mechanismOfAction
Sertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level.
n3:synonym
Sertindole 1-[2-[4-[5-chloro-1-(4-Fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one SerLect Serdolect Sertindol Sertindolum
n21:hasConcept
n22:M0182004
n3:IUPAC-Name
n4:271B48CB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B48D1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B48D0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B48CD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B48CE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B48CF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B48C9-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B48C7-363D-11E5-9242-09173F13E4C5 n4:271B48CA-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B48C8-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:N05AE03
n3:H-Bond-Acceptor-Count
n4:271B48D7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B48D8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B48D2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B48D3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B48D5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B48D4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B48D6-363D-11E5-9242-09173F13E4C5
n3:absorption
Orally available.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
106516-24-9
n3:category
n3:Bioavailability
n4:271B48DD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B48DF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B48E0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B48DC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B48DB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B48DE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B48CC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B48D9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B48DA-363D-11E5-9242-09173F13E4C5